#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	18096	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2051	873.4	0	.	n	.	0	A69G	SNP	69	69	A	293	293	G	1034	G,A	948,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	18096	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2051	873.4	0	.	n	.	0	C1450T	SNP	1450	1450	C	1674	1674	T	955	T,C	874,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	18096	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2051	873.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1408	1408	C	1118	C,A	1041,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33116	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3676	897.5	0	.	n	.	0	T695C	SNP	695	695	T	1082	1082	C	1024	C	956	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33116	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3676	897.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2358	2358	C	1031	C,T	958,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33116	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3676	897.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2432	2432	A	1000	A	949	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33116	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3676	897.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	2984	2984	C	1052	C,T	979,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2472	folP	855	855	100.0	folP.l6.c30.ctg.1	1516	162.0	1	SNP	p	R229S	1	.	.	685	687	AGC	1031	1033	AGC	273;271;271	A;G,A;C,T	253;249,1;252,1	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6498	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3412	189.5	1	SNP	p	S91F	1	.	.	271	273	TTC	658	660	TTC	197;198;198	T;T;C	187;188;188	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6498	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3412	189.5	1	SNP	p	G95N	0	.	.	283	285	GGC	670	672	GGC	202;201;200	G;G,A;C,T	191;187,1;188,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6498	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3412	189.5	1	SNP	p	D95G	1	.	.	283	285	GGC	670	672	GGC	202;201;200	G;G,A;C,T	191;187,1;188,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	2126	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1226	171.6	0	.	p	.	0	D79N	NONSYN	235	237	GAT	482	484	AAT	260;261;260	A;A;T,A	239;243;243,1	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	2126	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1226	171.6	1	SNP	p	G45D	0	.	.	133	135	GGC	380	382	GGC	293;297;296	G;G;C	269;268;272	mtrR.WHO_F_01564:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1146	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	915	123.2	0	.	n	.	0	A197.	DEL	197	197	A	545	545	A	250	A	230	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5698	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2885	196.1	0	.	p	.	0	E91G	NONSYN	271	273	GAG	594	596	GGG	231;233;232	G;G;G	208;207;207	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5698	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2885	196.1	1	SNP	p	D86N	0	.	.	256	258	GAC	579	581	GAC	230;229;229	G;A;C	210;205;209	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5698	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2885	196.1	1	SNP	p	S87R	0	.	.	259	261	AGT	582	584	AGT	233;233;234	A;G;T	209;210;204	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5698	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2885	196.1	1	SNP	p	S87I	0	.	.	259	261	AGT	582	584	AGT	233;233;234	A;G;T	209;210;204	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5698	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2885	196.1	1	SNP	p	S87W	0	.	.	259	261	AGT	582	584	AGT	233;233;234	A;G;T	209;210;204	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5698	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2885	196.1	1	SNP	p	S88P	0	.	.	262	264	TCC	585	587	TCC	235;232;232	T;C;C	210;207;209	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5310	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2547	206.8	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1568	1570	CAC	265;263;261	C;A;C	236;233;234	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5310	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2547	206.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1517	1519	GGC	263;263;259	G;G;C	242;245;238	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.44.001	penA.44.001	1	1	27	4862	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	197.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1333	1335	GCA	275;269;271	G;C,T;A,G	255;246,1;252,1	penA.44.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4862	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	197.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1336	1338	ATC	271;270;276	A;T;C	253;253;253	penA.44.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4862	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	197.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1348	1350	GTG	274;273;275	G;T;G	253;252;252	penA.44.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4862	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	197.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1348	1350	GTG	274;273;275	G;T;G	253;252;252	penA.44.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4862	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	197.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1852	1854	ACC	241;243;243	A;C;C	217;223;220	penA.44.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4862	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	197.0	1	SNP	p	T502P	0	.	.	1504	1506	ACG	1906	1908	ACG	224;227;226	A;C;G	184;190;178	penA.44.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4862	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	197.0	1	SNP	p	T502V	0	.	.	1504	1506	ACG	1906	1908	ACG	224;227;226	A;C;G	184;190;178	penA.44.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4862	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	197.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2029	2031	GGC	209;207;208	G;G;C	191;189;189	penA.44.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4862	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	197.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2038	2040	GGC	206;203;203	G;G;C	186;182;184	penA.44.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4862	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2457	197.0	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2056	2058	CTG	196;195;196	C,G;T;G	150,3;140;144	penA.44.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	7084	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3189	221.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1638	1640	CCG	261;264;259	C;C;G	235;242;233	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2796	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1812	153.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	612	612	C	207	C,T	194,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3718	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1696	218.0	0	.	p	.	0	T26A	NONSYN	76	78	ACC	447	449	GCC	323;322;323	G;C;C	309;307;308	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3718	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1696	218.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	483	485	GAA	315;317;317	G;A;A	300;303;305	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3718	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1696	218.0	0	.	p	.	0	N124S	NONSYN	370	372	AAT	741	743	AGT	297;295;297	A;G;T,C	284;283;282,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3718	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1696	218.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	771	773	GAT	286;287;288	G;A;T	268;269;266	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3718	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1696	218.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	894	896	TCA	334;332;333	T;C;A	301;303;304	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3718	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1696	218.0	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1023	1025	GTC	301;300;300	G;T;C	281;278;280	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3718	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1696	218.0	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1035	1037	TCT	299;297;298	T,C;C;T	280,1;278;280	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3718	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1696	218.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1353	1355	GCA	284;285;285	G,T;C;A	262,1;265;264	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3718	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1696	218.0	1	SNP	p	G120K	1	.	.	358	360	AAG	729	731	AAG	294;296;294	A;A;G	276;276;277	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3718	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1696	218.0	1	SNP	p	A121D	1	.	.	361	363	GAC	732	734	GAC	294;296;295	G;A;C	279;281;279	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3718	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1696	218.0	1	SNP	p	D121N	0	.	.	361	363	GAC	732	734	GAC	294;296;295	G;A;C	279;281;279	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	13492	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4747	282.6	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1918	1920	CAT	286;292;291	C,A;A;T	266,1;272;271	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1524	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1024	147.5	1	SNP	p	V57M	1	.	.	169	171	ATG	578	580	ATG	306;310;305	A;T;G	291;294;286	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
